CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio

The relapsed/refractory multiple myeloma market landscape is undergoing a radical transformation with the recent FDA approvals of two CAR-Ts which is opening up new avenues for companies developing later lines of therapy. Several key players are racing to bring their candidates to the market, and we estimate that a few CAR-Ts will join the fray by 2025. Some of the frontrunners in this space are Arcellx, Novartis, CARsgen Therapeutics, and others, who are harnessing the power of CAR-Ts for relapsed/refractory multiple myeloma.

LAS VEGAS, Sept. 25, 2023 /PRNewswire/ -- DelveInsight's CAR T-cell Therapy for Multiple Myeloma Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-cell therapy for multiple myeloma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the CAR T-cell Therapy for Multiple Myeloma Market Report

• According to DelveInsight analysis, the total market size of CAR-T in the United States for multiple myeloma was estimated to be nearly USD 400 million in 2022, which is expected to show positive growth by 2032.
• According to DelveInsight's estimates, there were around 47,000 frontline transplant-ineligible patients and 17,000 transplant-eligible patients of multiple myeloma patients in the 7MM in 2022. 
• Leading CAR T-cell therapy for multiple myeloma companies such as Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others are developing novel CAR T-cell therapies for multiple myeloma that can be available in the CAR T-cell therapy for multiple myeloma market in the coming years.
• Some key CAR T-cell therapies for multiple myeloma treatment include Descartes-11, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A), CTX120, CC-98633, bb21217, UCARTCS1A, CB-011, LMY-920, CYAD-211, ALLO-715 ± Nirogacestat, TEG002, CAR-T (CAR-GPRC5D), and others.

Discover which therapies are expected to grab the major CAR T-cell therapy for multiple myeloma market share @ CAR T-cell Therapy for Multiple Myeloma Market Report

Multiple Myeloma Overview

Multiple myeloma is the second most common hematological malignancy in the world, with a median age of onset of 60 years. This incurable cancer is caused by an overabundance of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. Multiple myeloma is a malignant illness defined by the uncontrolled proliferation of clonal plasma cells, which causes a variety of problems that eventually lead to organ malfunction and death. A recent modification in the pathophysiology of myeloma has resulted in significant advancements in the management of people with multiple myeloma. The formation of multidrug resistance (MDR), a process in which cancer cells resist different structurally and functionally unrelated medications following exposure to a single chemotherapeutic agent, is a key factor in treatment failure resulting in clinical relapse.

CAR-T Cell Therapy Overview

CAR-T cell therapy is a sort of cancer immunotherapy treatment that employs immune cells called T cells that have been genetically engineered in a lab to better locate and destroy cancer cells. CAR-T therapy can be particularly effective against certain types of cancer, even when other treatments are ineffective. Currently, the FDA has approved two CAR-T therapies to treat Multiple Myeloma: ABECMA (idecabtagene vicleucel) and CARVYKTI (ciltacabtagene autoleucel).

CAR T-cell Therapy for Multiple Myeloma Epidemiology Segmentation

The CAR T-cell therapy for multiple myeloma epidemiology section provides insights into the historical and current CAR T-cell therapy for multiple myeloma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The CAR T-cell therapy for multiple myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of Multiple Myeloma
• Total Symptomatic Cases of Multiple Myeloma
• Gender-Specific Cases of Multiple Myeloma
• Age-Specific Cases of Multiple Myeloma
• Transplant-Eligible Cases of Multiple Myeloma
• Treated Patient Pool Across all Lines of Therapies

CAR T-cell Therapy for Multiple Myeloma Treatment Market 

The multiple myeloma treatment is determined by the patient's symptoms as well as his or her overall health. Doctors frequently collaborate with patients to develop the optimal treatment approach. The therapy aims are to remove myeloma cells, restrict tumor growth, relieve pain, and enable patients to live an active life. While there is no cure for multiple myeloma, it can be successfully controlled in many individuals for many years. Treatment for persons with symptomatic myeloma includes both disease-controlling medication and supportive care to promote quality of life, such as symptom relief and proper nutrition. Multiple myeloma is commonly treated with a combination of three drugs, known as triplet therapy. A targeted therapy, an immunomodulator, and a corticosteroid are frequently used. With the FDA's approval of two CAR-Ts (CARVYKTI and ABECMA), the therapeutic choices for relapsed/refractory multiple myeloma have recently expanded dramatically, creating new opportunities for companies to develop treatments for later lines of treatment. 

CARVYKTI (Janssen) is a genetically engineered autologous T-cell immunotherapy that reprogrammes a patient's T cells with a transgene expressing a chimeric antigen receptor (CAR) that recognizes and destroys cells that express BCMA. The company plans to submit a Type II variation application to the European Medicines Agency (EMA) in May 2023, based on the CARTITUDE-4 study results, seeking approval of CARVYKTI for the earlier treatment of patients with relapsed and lenalidomide-refractory multiple myeloma.

ABECMA (ide-cel) is a genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapy co-developed and co-marketed by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. Bristol Myers Squibb, the maker of ABECMA, stopped its UK medicinal approval intentions in 2020 due to a variety of circumstances, including the impact of the pandemic on clinical trial delivery.

To know more about CAR T-cell therapy for multiple myeloma treatment, visit @ CAR T-cell Therapy Treatment 

American Society of Clinical Oncology (ASCO) 2023 Key Updates

• Johnson & Johnson's CARVYKTI emerges as a potential Standard of Care for Lenalidomide-Refractory Myeloma following the first relapse.
• Updated Phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients with Relapsed/refractory multiple myeloma.
• CARTITUDE-1 final results: Phase Ib/II study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Connect with our team to get key updates and detailed conference coverage from major Healthcare Conferences

Key CAR T-cell Therapies for Multiple Myeloma and Companies

• Descartes-11: Cartesian Therapeutics
• CART-ddBCMA: Arcellx
• PHE885: Novartis
• Orvacabtagene Autoleucel: Bristol-Myers Squibb
• Zevorcabtagene autoleucel (zevor-cel or CT053): CARsgen Therapeutics
• P-BCMA-ALLO1: Poseida Therapeutics
• CC-95266: Juno Therapeutics
• Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A): Nanjing IASO Biotherapeutics
• CTX120: CRISPR Therapeutics
• CC-98633: Juno Therapeutics
• bb21217: bluebird bio
• UCARTCS1A: Cellectis SA
• CB-011: Caribou Biosciences
• LMY-920: Luminary Therapeutics
• CYAD-211: Celyad Oncology
• ALLO-715 ± Nirogacestat: Allogene Therapeutics
• TEG002: Gadeta
• CAR-T (CAR-GPRC5D): Nanjing IASO Biotherapeutics

Learn more about the FDA-approved CAR T-cell therapy for multiple myeloma @ CAR T-cell Therapies for Multiple Myeloma Treatment 

CAR T-cell Therapy for Multiple Myeloma Market Dynamics

Multiple myeloma is a clonal plasma cell proliferative condition that is distinguished by an aberrant rise of monoclonal immunoglobulins. Excessive creation of these plasma cells, if unchecked, can eventually cause specific end-organ damage. This is most common when at least one of the following clinical symptoms is present: hypercalcemia, renal failure, anemia, or bone pain with lytic lesions. Because there is no precise cure, most patients relapse at some point. Adding to the concern about myeloma, some individuals do not respond to medication, becoming refractory and so known as relapsed/refractory multiple myeloma. Multiple myeloma is commonly treated with a combination of three drugs, known as triplet therapy. A targeted therapy, an immunomodulator, and a corticosteroid are frequently used.

With the recent FDA approvals of two CAR-Ts, the landscape of relapsed/refractory multiple myeloma is undergoing a profound upheaval, giving up new avenues for businesses to develop subsequent lines of therapy. Several significant competitors are rushing to bring their candidates to market, and we expect only a few CAR-Ts to join the race by 2025. Arcellx, Novartis, CARsgen Therapeutics, and others are among the companies harnessing the power of CAR-Ts for relapsed/refractory multiple myeloma. Two CAR-T therapies have been approved to treat multiple myeloma. Although CAR-T treatments have shown great efficacy, they are not without risks, such as CRS. Cost, convenience, and manufacturing turnaround time may initially prohibit CAR-T from becoming widely adopted, although corporations may lessen side effects and accelerate manufacturing time over time.

As per DelveInsight analysis, In the 4L+ scenario, approved CAR-Ts (ABECMA and CARVYKTI) generated about USD 500 million in the 7MM in 2022, and this figure is expected to climb as other emergent CAR-Ts are approved during the forecast period. In addition, among the emerging therapies in 4L+, CARsgen Therapeutics' zevorcabtagene autoleucel is expected to garner the highest market share in 2032 accounting for nearly USD 200 million.

Scope of the CAR T-cell Therapy for Multiple Myeloma Market Report

• Therapeutic Assessment: CAR T-cell Therapy for Multiple Myeloma current marketed and emerging therapies
• CAR T-cell Therapy for Multiple Myeloma Market Dynamics: Conjoint Analysis of Emerging CAR T-cell Therapy for Multiple Myeloma Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, CAR T-cell Therapy for Multiple Myeloma Market Access and Reimbursement

Discover more about CAR T-cell therapy for multiple myeloma in development @ CAR T-cell Therapy for Multiple Myeloma Clinical Trials

Table of Contents

Related Reports

CAR T-cell Therapy for Multiple Myeloma Pipeline

CAR T-cell Therapy for Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-cell therapy for multiple myeloma companies, including Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation, CARsgen Therapeutics, Poseida Therapeutics, Nanjing IASO Biotherapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Janssen, Pharmacyclics, Novartis, Incyte Corporation, Gracell Biotechnology, SpringWorks Therapeutics, Sana Biotechnology, Cytovia Therapeutics, Pfizer, MorphoSys, Biokine Therapeutics, Arcellx, Rapa Therapeutics, iTeos Therapeutics, Sorrento Therapeutics, CARsgen, Ascentage Pharma, Cartesian Therapeutics, Bristol-Myers Squibb, Juno Therapeutics, Nanjing IASO Biotherapeutics, Arch Oncology, Oncoceutics, TeneoBio, Nerviano Medical Sciences, among others.

CAR T-cell Therapy Competitive Landscape

CAR T-cell Therapy Competitive Landscape – 2023 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur  
[email protected]  
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED